This trial studies a targeted cancer cell killing monoclonal antibody in patients with B-cell acute lymphocytic leukemia who have positive minimal residual disease.
1 Primary · 3 Secondary · Reporting Duration: Up to 4 years
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: Inotuzumab Ozogamicin · No Placebo Group · Phase 2
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: